{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-031835","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.820989+00:00","generated_at":"2026-05-31T09:20:26.451072+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evofem Q2 net sales up 69% to $4.2M; operating loss improves 81% to $1.4M","bullets":["Net product sales $4.2M (+69% YoY); net income $1.3M ($0.02/share) vs net loss $8.6M ($5.43) in prior year.","Operating expenses down 43% to $5.5M; operating loss improved 81% to $1.4M.","Acquired global rights to SOLOSEC (secnidazole) for bacterial vaginosis and trichomoniasis.","Licensed Phexxi commercial rights in Middle East to Pharma 1 Drug Store; partnered with Hello Alpha.","Received $2.0M from Aditxt related to merger; targeting late 2024 close."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-031835","json":"https://secwatch.observer/filing/0001493152-24-031835.json","markdown":"https://secwatch.observer/filing/0001493152-24-031835.md","text":"https://secwatch.observer/filing/0001493152-24-031835.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224031835/0001493152-24-031835-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315224031835/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:20:26.451072+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}